Is Eli Lilly and Company (LLY) the Most Promising Dividend Stock According to Hedge Funds?
We recently compiled a list of the 10 Most Promising Dividend Stocks According to Hedge Funds. In this article, we are going ...
Business Insider10d
Eli Lilly & Co (LLY) Gets a Buy from Citi
Citi analyst Geoff Meacham maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed last Friday at $785.41. Meacham covers the Healthcare sector ...
Business Insider9d
Eli Lilly & Co. Receives Buy Rating from David Risinger Due to Promising Tirzepatide Trial Results and Competitive Tolerability
Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price target of $950.00. David Risinger has given his Buy rating ...
CBSSports.com5d
Lilly scores 34, Brown beats Pennsylvania 88-79
PHILADELPHIA (AP) Kino Lilly Jr. scored 34 points and made eight 3-pointers as Brown beat Pennsylvania 88-79 on Friday night. Lilly shot 9 for 16, including 8 for 9 from 3-point range, and 8 of 9 ...
Lilly Forecasts 2025 Profit Largely Above Estimates on Weight-Loss Drug Strength
On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...
Yahoo Finance12d
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
All of these are medications in Lilly's weight loss portfolio. However, another star performer throughout 2024 was Verzenio -- Lilly's main oncology treatment. For the nine months ended Sept.
FiercePharma6d
Novartis' Kisqali off to 'very rapid' launch in early breast cancer, CEO says. Can it keep up the momentum?
One of the most important launches for Novartis in recent years is off with a bang. Following a broad FDA approval for the adjuvant treatment of HR-positive, HER2-negative early breast cancer in ...